SROAX
Price
$12.96
Change
-$0.03 (-0.23%)
Updated
Jan 24 closing price
Net Assets
4.5M
VFFSX
Price
$298.70
Change
-$0.83 (-0.28%)
Updated
Jan 24 closing price
Net Assets
1.35T
Ad is loading...

SROAX vs VFFSX

Header iconSROAX vs VFFSX Comparison
Open Charts SROAX vs VFFSXBanner chart's image
Calamos Antetokounmpo Sustainable Eqs A
Price$12.96
Change-$0.03 (-0.23%)
VolumeN/A
Net Assets4.5M
Vanguard 500 Index Institutional Select
Price$298.70
Change-$0.83 (-0.28%)
VolumeN/A
Net Assets1.35T
SROAX vs VFFSX Comparison Chart
Loading...
View a ticker or compare two or three
VS
SROAX vs. VFFSX commentary
Jan 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SROAX is a Hold and VFFSX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
VFFSX has more cash in the bank: 1.35T vs. SROAX (4.5M). VFFSX pays higher dividends than SROAX: VFFSX (1.33) vs SROAX (0.27). SROAX was incepted earlier than VFFSX: SROAX (2 years) vs VFFSX (9 years). SROAX is a more actively managed with annual turnover of: 11.00 vs. VFFSX (2.00). SROAX has a lower initial minimum investment than VFFSX: SROAX (2500) vs VFFSX (5000000000). VFFSX annual gain was more profitable for investors over the last year : 25.81 vs. SROAX (17.07).
SROAXVFFSXSROAX / VFFSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence2 years9 years-
Gain YTD3.5894.09488%
Front LoadN/AN/A-
Min. Initial Investment250050000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets4.5M1.35T0%
Annual Yield % from dividends0.271.3321%
Returns for 1 year17.0725.8166%
Returns for 3 yearsN/A38.94-
Returns for 5 yearsN/A85.88-
Returns for 10 years-10.03N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLNN4.810.13
+2.78%
Clene Inc.
CASH78.901.59
+2.06%
Pathward Financial
RYN26.280.08
+0.31%
Rayonier
DDOG140.200.08
+0.06%
Datadog
ALDX5.03N/A
N/A
Aldeyra Therapeutics